Head-To-Head Analysis: Fortrea (FTRE) versus Its Competitors

Fortrea (NASDAQ:FTRE) is one of 45 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Fortrea to related businesses based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fortrea and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1	2	5	1	2.67
Fortrea Competitors	307	1189	2055	33	2.51

Fortrea currently has a consensus target price of $34.43, suggesting a potential upside of 33.96%. As a group, “Medical laboratories” companies have a potential upside of 23.99%. Given Fortrea’s stronger consensus rating and higher probable upside, equities analysts clearly believe Fortrea is more favorable than its rivals.

Profitability

This table compares Fortrea and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-4.11%	4.76%	1.87%
Fortrea Competitors	-3,440.01%	-406.24%	-38.38%

Valuation & Earnings

This table compares Fortrea and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fortrea	$3.11 billion	-$3.40 million	-18.49
Fortrea Competitors	$1.03 billion	-$127.26 million	4.40

Fortrea has higher revenue and earnings than its rivals. Fortrea is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

48.3% of shares of all “Medical laboratories” companies are held by institutional investors. 0.1% of Fortrea shares are held by insiders. Comparatively, 17.3% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortrea beats its rivals on 8 of the 12 factors compared.

Fortrea Company Profile

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.